Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$71.19
+0.6%
$78.68
$66.49
$87.77
$6.58B1.31560,294 shs454,423 shs
Chemed Co. stock logo
CHE
Chemed
$617.56
+0.2%
$623.23
$492.84
$654.62
$9.34B0.4277,478 shs67,370 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$39.12
+0.4%
$39.71
$29.85
$45.00
$4.97B1.251.24 million shs620,516 shs
Masimo Co. stock logo
MASI
Masimo
$135.92
-0.8%
$135.65
$75.22
$195.82
$7.19B0.97564,592 shs232,180 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
+0.68%-0.34%-7.52%-14.40%-4.24%
Chemed Co. stock logo
CHE
Chemed
+1.98%+1.33%-4.97%+4.05%+8.69%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.67%+1.54%-2.77%+11.18%+16.19%
Masimo Co. stock logo
MASI
Masimo
+1.96%-0.89%+1.50%+11.90%-30.15%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
4.6015 of 5 stars
4.42.00.05.03.10.81.3
Chemed Co. stock logo
CHE
Chemed
4.8262 of 5 stars
2.53.03.34.92.62.52.5
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.9231 of 5 stars
3.42.00.04.42.72.54.4
Masimo Co. stock logo
MASI
Masimo
3.9945 of 5 stars
2.23.00.04.22.11.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
2.71
Moderate Buy$94.7533.09% Upside
Chemed Co. stock logo
CHE
Chemed
3.00
Buy$681.0010.27% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.86
Moderate Buy$53.2936.21% Upside
Masimo Co. stock logo
MASI
Masimo
2.43
Hold$137.431.11% Upside

Current Analyst Ratings

Latest ACHC, MASI, CHE, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/16/2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/15/2024
Masimo Co. stock logo
MASI
Masimo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$148.00 ➝ $170.00
3/25/2024
Masimo Co. stock logo
MASI
Masimo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$125.00 ➝ $148.00
3/25/2024
Masimo Co. stock logo
MASI
Masimo
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$145.00 ➝ $166.00
3/25/2024
Masimo Co. stock logo
MASI
Masimo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$117.00 ➝ $160.00
3/6/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$77.00 ➝ $84.00
3/6/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$100.00
3/5/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$90.00
3/4/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$94.00
3/4/2024
Chemed Co. stock logo
CHE
Chemed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$604.00 ➝ $712.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$2.93B2.25$4.96 per share14.36$30.17 per share2.36
Chemed Co. stock logo
CHE
Chemed
$2.26B4.12$25.09 per share24.61$73.55 per share8.40
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$829.25M5.99$3.21 per share12.18$0.63 per share62.10
Masimo Co. stock logo
MASI
Masimo
$2.05B3.51$5.83 per share23.30$25.79 per share5.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
-$21.67M-$0.25N/A17.982.07-0.74%11.21%6.04%5/1/2024 (Confirmed)
Chemed Co. stock logo
CHE
Chemed
$272.51M$17.9234.4625.702.4312.03%32.29%20.74%4/24/2024 (Confirmed)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$281.59M$2.1118.549.160.4533.96%248.20%19.13%5/7/2024 (Confirmed)
Masimo Co. stock logo
MASI
Masimo
$81.50M$1.5190.0135.58N/A3.98%13.77%5.98%5/7/2024 (Confirmed)

Latest ACHC, MASI, CHE, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.64N/A-$0.64N/AN/AN/A  
5/7/2024N/A
Masimo Co. stock logo
MASI
Masimo
$0.71N/A-$0.71N/AN/AN/A  
5/1/2024N/A
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$0.80N/A-$0.80N/AN/AN/A  
4/24/2024N/A
Chemed Co. stock logo
CHE
Chemed
$5.09$5.20+$0.11N/A$591.46 million$589.20 million  
2/28/2024Q4 2023
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$0.80$0.85+$0.05$1.07$727.60 million$742.80 million    
2/27/2024Q4 2023
Chemed Co. stock logo
CHE
Chemed
$6.25$6.60+$0.35$7.30$586.64 million$585.90 million    
2/27/2024Q4 2023
Masimo Co. stock logo
MASI
Masimo
$0.82$1.25+$0.43$1.87$545.69 million$548.90 million    
2/20/2024Q4 2023
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.77$0.75-$0.02$0.85$235.25 million$230.04 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/AN/AN/AN/AN/A
Chemed Co. stock logo
CHE
Chemed
$1.600.26%+5.73%8.93%15 Years
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Masimo Co. stock logo
MASI
Masimo
N/AN/AN/AN/AN/A

Latest ACHC, MASI, CHE, and HALO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2024
Chemed Co. stock logo
CHE
Chemed
quarterly$0.400.27%2/23/20242/26/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
0.48
0.67
0.67
Chemed Co. stock logo
CHE
Chemed
N/A
1.61
1.57
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
17.89
6.64
5.50
Masimo Co. stock logo
MASI
Masimo
0.64
2.18
1.22

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/A
Chemed Co. stock logo
CHE
Chemed
95.85%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Masimo Co. stock logo
MASI
Masimo
85.96%

Insider Ownership

CompanyInsider Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
2.80%
Chemed Co. stock logo
CHE
Chemed
3.32%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.40%
Masimo Co. stock logo
MASI
Masimo
9.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
23,50092.43 million89.84 millionOptionable
Chemed Co. stock logo
CHE
Chemed
15,08715.12 million14.62 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
373127.05 million123.62 millionOptionable
Masimo Co. stock logo
MASI
Masimo
5,20052.91 million47.78 millionOptionable

ACHC, MASI, CHE, and HALO Headlines

SourceHeadline
Specifi partners with Masimo’s audio brandsSpecifi partners with Masimo’s audio brands
installation-international.com - April 24 at 4:51 PM
Masimo to Report First Quarter 2024 Financial Results after Market Close on Tuesday, May 7Masimo to Report First Quarter 2024 Financial Results after Market Close on Tuesday, May 7
businesswire.com - April 23 at 8:00 AM
Masimo (NASDAQ:MASI) Updates FY 2024 Earnings GuidanceMasimo (NASDAQ:MASI) Updates FY 2024 Earnings Guidance
americanbankingnews.com - April 22 at 7:36 AM
Apple Watch Series 9 Hits All-Time Low Special Offer PriceApple Watch Series 9 Hits All-Time Low Special Offer Price
forbes.com - April 22 at 12:23 AM
6 Reasons Cracker Barrel Is Struggling6 Reasons Cracker Barrel Is Struggling
msn.com - April 21 at 7:23 PM
Kornitzer Capital Management Inc. KS Invests $6.21 Million in Masimo Co. (NASDAQ:MASI)Kornitzer Capital Management Inc. KS Invests $6.21 Million in Masimo Co. (NASDAQ:MASI)
marketbeat.com - April 21 at 8:14 AM
Sumitomo Mitsui Trust Holdings Inc. Has $48.50 Million Stake in Masimo Co. (NASDAQ:MASI)Sumitomo Mitsui Trust Holdings Inc. Has $48.50 Million Stake in Masimo Co. (NASDAQ:MASI)
marketbeat.com - April 20 at 5:41 AM
Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?
zacks.com - April 19 at 1:15 PM
Reasons Why You Should Retain Masimo (MASI) Stock for NowReasons Why You Should Retain Masimo (MASI) Stock for Now
zacks.com - April 19 at 12:47 PM
Readystate Asset Management LP Makes New $3.22 Million Investment in Masimo Co. (NASDAQ:MASI)Readystate Asset Management LP Makes New $3.22 Million Investment in Masimo Co. (NASDAQ:MASI)
marketbeat.com - April 17 at 10:38 PM
Masimo (NASDAQ:MASI) Updates Q1 2024 Earnings GuidanceMasimo (NASDAQ:MASI) Updates Q1 2024 Earnings Guidance
marketbeat.com - April 17 at 3:42 PM
Masimo (MASI) Gains Nearly 18% YTD: Whats Driving the Rally?Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
finance.yahoo.com - April 17 at 9:25 AM
Masimo (MASI) Gains Nearly 18% YTD: Whats Driving the Rally?Masimo (MASI) Gains Nearly 18% YTD: What's Driving the Rally?
zacks.com - April 17 at 8:46 AM
Masimo (NASDAQ:MASI) Shares Gap Up to $137.92Masimo (NASDAQ:MASI) Shares Gap Up to $137.92
americanbankingnews.com - April 17 at 5:14 AM
Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in ChileMasimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile
businesswire.com - April 16 at 8:00 AM
Masimo (NASDAQ:MASI) Upgraded to Buy at Stifel NicolausMasimo (NASDAQ:MASI) Upgraded to Buy at Stifel Nicolaus
americanbankingnews.com - April 16 at 4:46 AM
Stifel Upgrades Masimo (MASI)Stifel Upgrades Masimo (MASI)
msn.com - April 16 at 12:28 AM
Buy Rating Affirmed for Masimo: Strategic Developments and Positive Outlook Signal GrowthBuy Rating Affirmed for Masimo: Strategic Developments and Positive Outlook Signal Growth
markets.businessinsider.com - April 15 at 2:26 PM
Forecasting The Future: 6 Analyst Projections For MasimoForecasting The Future: 6 Analyst Projections For Masimo
markets.businessinsider.com - April 15 at 2:26 PM
Masimo (NASDAQ:MASI) Stock Rating Upgraded by Stifel NicolausMasimo (NASDAQ:MASI) Stock Rating Upgraded by Stifel Nicolaus
marketbeat.com - April 15 at 8:16 AM
Is There An Opportunity With Masimo Corporations (NASDAQ:MASI) 24% Undervaluation?Is There An Opportunity With Masimo Corporation's (NASDAQ:MASI) 24% Undervaluation?
finance.yahoo.com - April 14 at 12:30 PM
Arrogant Apple Goes ‘Ape Shit’ Over Watch Ban, With 900+ With Appeal Document That Spews Out Wild Claims Against Masimo & SonosArrogant Apple Goes ‘Ape Shit’ Over Watch Ban, With 900+ With Appeal Document That Spews Out Wild Claims Against Masimo & Sonos
channelnews.com.au - April 10 at 8:36 PM
Masimo To Explore Spin-Off Of Its Consumer UnitMasimo To Explore Spin-Off Of Its Consumer Unit
forbes.com - April 10 at 3:35 PM
A Busy Docket for Device Maker MasimoA Busy Docket for Device Maker Masimo
ocbj.com - April 8 at 4:31 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Acadia Healthcare logo

Acadia Healthcare

NASDAQ:ACHC
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Chemed logo

Chemed

NYSE:CHE
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Halozyme Therapeutics logo

Halozyme Therapeutics

NASDAQ:HALO
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Masimo logo

Masimo

NASDAQ:MASI
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.